Long COVID is estimated to lead to about $2b-$6.5b of related costs/year for the ~44 to 48m people suffering in the U.S. but no treatment has proven effective yet. Aethlon collaborated with the UCSF Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID symptoms & examine whether they could benefit from the Hemopurifier. We estimate, given the company's focus on controlling costs, that expense associated with this effort was de minimis. We also estimate that the data shows results that warrant further study of the Hemopurifier for Long Covid and potentially other areas of infectious disease. Separately, AEMD recently published papers on preclinical data showing the Hemopurifier's ability to remove platelet-derived EVs from plasma and preclinical data on the Hemopurifier in the Transplant Immunology Journal.
